MB
TSHA icon

MPM BioImpact’s Taysha Gene Therapies TSHA Stock Holding History

MPM BioImpact’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.6M Buy
+4,500,000
New +$26.6M 1.87% 21
2025
Q3 		– Sell
-2,953,562
Closed -$6.82M – 49
2025
Q2 		$6.82M Buy
+2,953,562
New +$6.42M 1.18% 36

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MPM BioImpact's TSHA Position: Q2 2026 in Review

MPM BioImpact opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 4,500,000 shares worth $30.6M. The stake represents 1.87% of the portfolio and ranks #21 among its holdings. This is a return to the name: MPM BioImpact previously reported a position in TSHA as recently as Q2 2025.

MPM BioImpact first reported a position in TSHA in Q2 2025 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • MPM BioImpact held 4,500,000 shares of Taysha Gene Therapies worth $30.6M as of Q2 2026.
  • Taysha Gene Therapies was a new MPM BioImpact position in Q2 2026.
  • Taysha Gene Therapies made up 1.87% of MPM BioImpact's portfolio in Q2 2026, its #21 holding.
  • MPM BioImpact first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.